Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-26T05:36:24.288Z Has data issue: false hasContentIssue false
  • English
  • Français

Long Term Intrathecal Baclofen Therapy in Patients with Intractable Spasticity

Published online by Cambridge University Press:  18 September 2015

W.J. Becker ,
C.J. Harris ,
M.L. Long ,
D.P. Ablett ,
G.M. Klein  and
D.A. DeForge
W.J. Becker*
Affiliation:
University of Calgary and the Calgary General Hospital, Calgary
C.J. Harris
Affiliation:
University of Calgary and the Calgary General Hospital, Calgary
M.L. Long
Affiliation:
University of Calgary and the Calgary General Hospital, Calgary
D.P. Ablett
Affiliation:
University of Calgary and the Calgary General Hospital, Calgary
G.M. Klein
Affiliation:
University of Calgary and the Calgary General Hospital, Calgary
D.A. DeForge
Affiliation:
University of Calgary and the Calgary General Hospital, Calgary
*
Calgary General Hospital, M6-012, 841 Centre Avenue E., Calgary, Alberta, Canada T2E 0A1.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Severe spasticity unresponsive to oral drugs may respond satisfactorily to baclofen delivered intrathecally.

Methods

Intrathecal baclofen (IB) therapy delivered by means of implanted infusion pumps was used for nine patients with severe spasticity. Six patients had multiple sclerosis, two cervical spinal cord injury, and one head injury. All were non-ambulatory.

Results

Patients showed improvement in many areas, including ability to transfer, seating, pain control, personal care, and liability to skin breakdown. Before IB therapy, only three of the nine patients were able to live at home in the community and six were institutionalized. At the end of our follow-up period, only one patient remained institutionalized, three lived in group homes and five lived at home in the community. In the year preceding pump implantation, the nine patients spent a total of 755 days in acute care hospitals. In the year following onset of IB therapy, they spent only 259 days in hospital.

Conclusions

IB therapy can improve patient quality of life and can be cost-effective in carefully selected patients with severe spasticity and disability. The drug delivery catheter is that part of the therapeutic system most vulnerable to failure. Because of the varied expertise required to manage these patients effectively, and the potential for a variety of complications, it is essential that an IB program is supported by a well-organized multi-disciplinary medical team.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 22 , Issue 3 , August 1995 , pp. 208 - 217
Copyright
Copyright © Canadian Neurological Sciences Federation 1995

References

1.Penn, RD, Kroin, JS.Continuous intrathecal baclofen for severe spasticity. Lancet 1985; 125–127.CrossRefGoogle Scholar
2.Penn, RD, Kroin, JS.Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 1987; 66: 181–185.CrossRefGoogle ScholarPubMed
3.Penn, RD, Savoy, SM, Crocos, D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517–1521.CrossRefGoogle ScholarPubMed
4.Zierski, J, Muller, H, Draile, D, Wurdinger, T.Implanted pump systems for treatment of spasticity. Acta Neurochir 1988; Suppl 13: 94–99.Google Scholar
5.Ochs, G, Struppler, A, Meyerson, BA, et al. Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. J Neurol Neurosurg Psychiatr 1989; 52: 933–939.CrossRefGoogle ScholarPubMed
6.Loubser, PG, Narayan, RK, Sandin, KJ, Donovan, WH, Russell, KD.Continuous infusion of intrathecal baclofen: long-term effects on spasticity inspinal cord injury. Paraplegia 1991; 29: 48–64.Google ScholarPubMed
7.Broseta, J, Garcia-March, G, Sanchez-Ledesma, J, Anaya, J, Silva, I.Chronic intrathecal baclofen administration in severe spasticity. Stereotact Funct Neurosurg 1990; 54+55: 147–153.CrossRefGoogle ScholarPubMed
8.Lazorthes, Y, Sallerin-Caute, B, Verdie, J-C, Bastide, R, Carillo, J-P.Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg 1990; 72: 393–402.CrossRefGoogle ScholarPubMed
9.Meythaler, JM, Steers, WD, Tuel, SM, Cross, LL, Haworth, CS.Continuous intrathecal baclofen in spinal cord spasticity: a prospective study. Am J Phys Med Rehabil 1992; 71: 321–327.CrossRefGoogle ScholarPubMed
10.Coffey, RJ, Cahil, D, Steers, W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicentre study. J Neurosurg 1993; 78: 226–232.CrossRefGoogle Scholar
11.Penn, RD.Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992; 77: 236–240.CrossRefGoogle ScholarPubMed
12.Albright, AL, Cervi, A, Singletary, J.Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991; 265: 1418–1422.CrossRefGoogle ScholarPubMed
13.Braunsdorf, WE, Kuhlendahl, HD, Volkheimer, A, Behrens, C, Kleiter, K.Continuous intrathecal baclofen therapy using an implantable pump system insevere spasticity. Neurochirurgia 1990; 33: 16–19.Google Scholar
14.Kroin, JS, Bianchi, GD, Penn, RD.Intrathecal baclofen down-regulates GABA, receptors in the rat substantia gelatinosa. J Neurosurg 1993; 79: 544–549.CrossRefGoogle ScholarPubMed
15.Edwards, FR, Harrison, PJ, Jack, JJB, Kullman, DM.Reduction by baclofen of monosynaptic EPSPs in lumbosacral motoneurones of the anesthetized cat. J Physiol 1989; 416: 539–556.CrossRefGoogle Scholar
16.Peng, Y-y, Frank, E.Activation of GABAB receptors causes presynaptic inhibition at synapses between muscle spindle afferents and motoneurons in the spinal cord of bullfrogs. J Neurosci 1989; 9: 1502–1515.CrossRefGoogle ScholarPubMed
17.Azouvi, P, Roby-Brami, A, Biraben, A, et al. Effect of intrathecal baclofen on the monosynaptic reflex in humans: evidence for a postsynaptic action. J Neurol Neurosurg Psychiatr 1993; 56: 515–519.CrossRefGoogle ScholarPubMed
18.Kroin, JS, Ali, A, York, M, Penn, RD.The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery 1993; 33: 226–230.CrossRefGoogle ScholarPubMed
19.Kroin, JS, Penn, RD.Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen. In: Lakke, JPWF, Delhaas, EM, Rutgers, AWF, eds. Parenteral Drug Therapy in Spasticity and Parkinson’s Disease. Carnforth, UK, Parthenon Publishing, 1991: 73–83.Google Scholar
20.Erickson, DL, Blacklock, JB, Michaelson, M, Sperling, KB, Lo, JN.Control of spasticity by implantable continuous flow morphine pump. Neurosurgery 1985; 16: 215–217.CrossRefGoogle ScholarPubMed
21.Putty, TK, Shapiro, SA.Efficacy of dorsal longitudinal myelotomy in treating spinal spasticity: a review of 20 cases. J Neurosurg 1991; 75: 397–401.CrossRefGoogle ScholarPubMed
22.Steinbok, P, Reiner, A, Beauchamp, RD, et al. Selective functional posterior phizotomy for treatment of spastic cerebral palsy in children. Ped Neurosurg 1992; 18: 34–42.CrossRefGoogle ScholarPubMed
23.Siegfried, RN, Jacobson, L, Chabal, C.Development of an acute withdrawal syndrome following the cessation of intrathecal baclofen in a patient with spasticity. Anesthesiology 1992; 77: 1048–1050.CrossRefGoogle Scholar
24.Nanninga, JB, Frost, F, Penn, R.Effect of intrathecal baclofen on bladder and sphincter function. J Urol 1989; 142: 101–105.CrossRefGoogle ScholarPubMed
25.Frost, F, Nanninga, J, Penn, R, Savoy, S, Wu, Y.Intrathecal baclofen infusion: effect on bladder management programs in patients with myelopathy. Am J Phys Med Rehab 1989; 68: 112–115.CrossRefGoogle ScholarPubMed
26.Latash, ML, Penn, RD, Corcos, DM, Gottlier, GL.Effects of intrathecal baclofen on voluntary motor control in spastic paresis. J Neurosurg 1990; 72: 388–392.CrossRefGoogle ScholarPubMed